Navigation Links
Lilly's Investigational GLP-1 Receptor Agonist, Dulaglutide, Showed Superior Glycemic Control Versus Comparators in Patients with Type 2 Diabetes
Date:6/22/2013

as mostly mild to moderate and transient. No new safety signals were seen in any of the studies.

Dulaglutide showed low rates of hypoglycemia (blood glucose level less than or equal to 70 mg/dL) across these three AWARD trials. There were no cases of documented severe hypoglycemia in any of the trials.

"These results are a promising step forward in our effort to provide a new, once-weekly GLP-1 treatment option, giving patients another choice to help manage their diabetes," said Sherry Martin, M.D., senior medical director, Lilly Diabetes. "Dulaglutide represents an important component of our diabetes portfolio, as it could help us offer a broader range of options to patients across the diabetes spectrum."

Dulaglutide is among several diabetes molecules in Lilly's late-stage pipeline. The company has a number of potential new medicines in clinical development for the treatment of diabetes and its related conditions, encompassing both large and small molecules, and targeting a variety of mechanisms. Lilly expects to submit dulaglutide to regulatory authorities in 2013 and to submit detailed data from two additional AWARD studies for presentation at scientific meetings in 2014.

About the AWARD (Assessment of Weekly AdministRation of LY2189265 in Diabetes) Studies
AWARD-1 was a randomized, 52-week, placebo-controlled comparison of the effects of dulaglutide and exenatide on glycemic control in patients with type 2 diabetes on metformin and pioglitazone. The primary objective of the study, conducted in 978 patients, was to evaluate whether dulaglutide 1.5 mg, dosed once-weekly, is superior to placebo in reducing HbA1c from baseline at 26 weeks.

AWARD-3 was a randomized, 52-week, double-blind comparison of the effects of dulaglutide and metformin on glycemic control in patients with early type 2 diabetes. The primary objective of the study, conducted in 807 pati
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
2. Oramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin
3. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
4. Upsher-Smith Currently Recruiting People With Epilepsy To Evaluate Investigational Rescue Treatment For Seizure Clusters
5. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
6. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
7. Can a genetic variation in the vitamin D receptor protect against osteoporosis?
8. ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
9. Receptos Co-Publishes Highest Resolution G-Protein Coupled Receptor Structure to Date in Science
10. Receptos Scientists Publish Determination of a High Resolution Sphingosine 1-Phosphate Receptor 1 Structure in Science
11. Superior Controls of Seabrook, NH named Business of the Year for 2013 by Business NH Magazine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... Md. , Jan. 14, 2014  Organovo announced today ... the National Institutes of Health (NIH) to help scientists ... treatments to patients on a faster timeline. Organovo is ... (NCATS) and the National Eye Institute (NEI) to develop ...
(Date:1/14/2014)... Kinaxis ®, provider of RapidResponse ®, a cloud-based supply ... ( S&OP ) service, is proud to be a gold ... held at the Hilton San Diego Bayfront, January 30 – ... Kaszas , Director of Supply Chain at Amgen, as she ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that ... company update at the Deutsche Bank 34th Annual Health Care ... p.m. ET. Interested parties may access a live audio ... the BioMarin website, www.BMRN.com . A ...
... platform for treatment of Spinal Muscular Atrophy SOUTH PLAINFIELD, ... Inc. (PTC) and the Spinal Muscular Atrophy (SMA) Foundation ... which the SMA Foundation will provide up to $8.5 ... second continuation of the collaboration to fund a series ...
... AND STRENGTHENS ITS SENIOR MANAGEMENT TEAM , ... Systems, Inc. (OTC Bulletin Board: OMCM.OB), a leader in ... today announced that it has strengthened its European presence ... Summa. As Executive Vice President, Europe & Asia/Pacific based ...
Cached Biology Technology:BioMarin to Present at the Deutsche Bank Health Care Conference 2PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration 2PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration 3OmniComm Systems Appoints EDC Veteran Dr. Wolfgang Summa to Executive Vice President, Europe & Asia/Pacific 2OmniComm Systems Appoints EDC Veteran Dr. Wolfgang Summa to Executive Vice President, Europe & Asia/Pacific 3
(Date:7/10/2014)... and teens living with a cardiac pacemaker, a low ... of life, reports a study in the July ... the official journal of the Society for Developmental ... by Lippincott Williams & Wilkins , a part ... function as a protective factor against lower health-related quality ...
(Date:7/10/2014)... image was collected by the Moderate Resolution Imaging Spectroradiometer ... Each hot spot, which appears as a red mark, ... MODIS instrument recognized temperatures higher than background. When accompanied ... hot spots are diagnostic for fire. , This ... coming directly from the fires, although the smoke released ...
(Date:7/10/2014)... some patients, the chronic inflammatory skin diseases psoriasis* and ... have therefore had to base their decision on which ... an examination of tissue samples. A team of researchers ... of Munich (TUM) have now analyzed the molecular processes ... This has enabled them for the first time to ...
Breaking Biology News(10 mins):For children with pacemakers, 'self-competence' affects quality of life 2New diagnostic test to distinguish psoriasis from eczema 2
... Science-based identification of mold and other causes of ... plant pathologists with The American Phytopathological Society (APS). ... situation in which building occupants experience health problems ... typically associated with SBS range from allergy attacks ...
... South Korean team announced last week that it had ... that were genetically matched to specific people. But their ... Yuri Verlinsky of the Reproductive Genetics Institute, based in ... without resorting to therapeutic cloning. "It would be a ...
... When genes are deleted on a particular section of ... the childhood cancer neuroblastoma. A new study suggests that ... children with neuroblastoma may indicate to physicians that they ... fight the cancer. , Edward F. Attiyeh, M.D., a ...
Cached Biology News:What's really making you sick? Plant pathologists offer the science behind Sick Building Syndrome 2Double triumph in stem cell quest 2Double triumph in stem cell quest 3Double triumph in stem cell quest 4Chromosome Deletion Predicts Aggressive Neuroblastoma 2
Alkaline Phosphatase (E. coli C75), 100 units. Removes 5'-phosphates from DNA. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Alkaline Phosphatases....
... CyScribe First-Strand cDNA Labeling System - ... 50 reactions. For the generation and ... reagents are packaged together for complete ... protocols can be used for performing ...
... Post-Labeling Reactive Dye Pack, 12 x ... specifically optimized for microarray labeling.Higher reactivity ... reactive dye per vial, at > ... individually dispensed, and packed in foil ...
... CyScribe GFX Purification Kit, 24 reactions. ... Cy3- and Cy5-labeled cDNA.Optimized reagents are ... and purification.Flexible and optimized protocols can ... with either Cy3- or Cy5-labeled nucleotides.Reliable ...
Biology Products: